Compare Incyte Corporation (INCY) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Orion Office REIT Inc — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Orion Office REIT Inc trades at $2.8 (market cap $158.01M). The key difference: Incyte Corporation is far larger — about 155.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ONL | |
|---|---|---|
Market Cap | $24.54B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $129.93 | $3.04 |
52-Week Low | $81.61 | $1.93 |
Enterprise Value | $20.04B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
ONL trades at $2.76, up 0.36% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $0.42 versus -$0.07 expected, but maintains negative net income and ROE. Revenue has declined from $208M in 2022 to $148M in 2025, with a net loss of -$139M. Analyst consensus is split evenly between Buy and Hold.
The outlook remains challenged by persistent losses and declining revenue, though the low P/B of 0.25 suggests asset value. Key risks include high debt and weak profitability. Upside depends on successful portfolio repositioning and a return to sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
